Nanoparticle-based drug delivery systems to overcome gastric cancer drug resistance

被引:41
作者
Nejati, Kazem [1 ]
Rastegar, Mojgan [2 ]
Fathi, Farzaneh [1 ]
Dadashpour, Mehdi [3 ]
Arabzadeh, AmirAhmad [4 ]
机构
[1] Ardabil Univ Med Sci, Pharmaceut Sci Res Ctr, Ardebil, Iran
[2] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Biochem & Med Genet, Winnipeg, MB, Canada
[3] Semnan Univ Med Sci, Dept Med Biotechnol, Semnan, Iran
[4] Ardabil Univ Med Sci, Sch Med, Dept Surg, Ardebil, Iran
关键词
Gastric cancer; Chemotherapy; Nano-delivery systems; Multi-drug resistance; Chemoresistance; MESOPOROUS SILICA NANOPARTICLES; GLUTATHIONE S-TRANSFERASES; SOLID LIPID NANOPARTICLES; MULTIDRUG-RESISTANCE; POLYMERIC MICELLES; CARBON NANOTUBES; CO-DELIVERY; GOLD NANOPARTICLES; ANTICANCER DRUGS; TOPOISOMERASE-II;
D O I
10.1016/j.jddst.2022.103231
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gastric cancer (GC) results from deregulated cell growth in the stomach. Despite significant efforts and recent advancements in the treatment of gastric cancer, it remains a life-threatening disease. This is in part due to the chemotherapy failure resulting from multi-drug resistance (MDR) in the associated Gastric cancer cells (GCC). These cells can acquire MDR through different mechanisms. Perhaps the most important mechanism would be the increased drug efflux by ATP-binding cassette (ABC) transporters, which reduces the intracellular concentration of the chemotherapy drugs. Recently, nanoparticle-based drug delivery systems (nano-DDS) have been emerged to reverse MDR by altering the mechanisms through which the drugs may function. Nano-DDSs are also highly regarded because of their potential to enhance the pharmacological profile of chemotherapy drugs, improving drug solubility, and decrease their adverse effects. This review summarizes known factors that are involved in the MDR of GCC. Additionally, we will describe the application of nano-DDSs to reverse MDR in GCC.
引用
收藏
页数:10
相关论文
共 166 条
[41]   Engineering gold-based radiosensitizers for cancer radiotherapy [J].
Goswami, Nirmal ;
Luo, Zhentao ;
Yuan, Xun ;
Leong, David Tai ;
Xie, Jianping .
MATERIALS HORIZONS, 2017, 4 (05) :817-831
[42]   The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research [J].
Gottesman, MM ;
Ling, V .
FEBS LETTERS, 2006, 580 (04) :998-1009
[43]   Vitamin B12-conjugated sericin micelles for targeting CD320-overexpressed gastric cancer and reversing drug resistance [J].
Guo, Weihong ;
Deng, Lizhi ;
Chen, Zhaoyu ;
Chen, Zhian ;
Yu, Jiang ;
Liu, Hao ;
Li, Tuanjie ;
Lin, Tian ;
Chen, Hao ;
Zhao, Mingli ;
Zhang, Liming ;
Li, Guoxin ;
Hu, Yanfeng .
NANOMEDICINE, 2019, 14 (03) :353-370
[44]   Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells [J].
Guo, Xianling ;
Ma, Nannan ;
Wang, Jin ;
Song, Jianrui ;
Bu, Xinxin ;
Cheng, Yue ;
Sun, Kai ;
Xiong, Haiyan ;
Jiang, Guocheng ;
Zhang, Baihe ;
Wu, Mengchao ;
Wei, Lixin .
BMC CANCER, 2008, 8 (1)
[45]   Glutathione S-transferase polymorphisms and their biological consequences [J].
Hayes, JD ;
Strange, RC .
PHARMACOLOGY, 2000, 61 (03) :154-166
[46]   Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy [J].
Hoosain, Famida G. ;
Choonara, Yahya E. ;
Tomar, Lomas K. ;
Kumar, Pradeep ;
Tyagi, Charu ;
du Toit, Lisa C. ;
Pillay, Viness .
BIOMED RESEARCH INTERNATIONAL, 2015, 2015
[47]   Drug Resistance in Cancer: An Overview [J].
Housman, Genevieve ;
Byler, Shannon ;
Heerboth, Sarah ;
Lapinska, Karolina ;
Longacre, Mckenna ;
Snyder, Nicole ;
Sarkar, Sibaji .
CANCERS, 2014, 6 (03) :1769-1792
[48]   The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer [J].
Hu, Wen-Qing ;
Peng, Chun-Wei ;
Li, Yan .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2009, 28
[49]   The use of lipid-based nanocarriers for targeted pain therapies [J].
Hua, Susan ;
Wu, Sherry Y. .
FRONTIERS IN PHARMACOLOGY, 2013, 4
[50]   Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study [J].
Irajirad, Rasoul ;
Ahmadi, Amirhossein ;
Najafabad, Bahareh Khalili ;
Abed, Ziaeddin ;
Sheervalilou, Roghayeh ;
Khoei, Samideh ;
Shiran, M. Bagher ;
Ghaznavi, Habib ;
Shakeri-Zadeh, Ali .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) :1315-1321